



AMERICAN  
SOCIETY FOR  
MICROBIOLOGY

# Microbiology Spectrum

## Diagnosis of fasciolosis antibodies in Brazilian cattle through enzyme-linked immunosorbent assay (ELISA) employing both native and recombinant antigens

GUILHERME DRESCHER, Hellen dos Santos, Mariane Pinto, Luis Morello, and Fabiano Figueiredo

*Corresponding Author(s): GUILHERME DRESCHER, Instituto Carlos Chagas*

---

### Review Timeline:

Submission Date:	January 9, 2024
Editorial Decision:	February 11, 2024
Revision Received:	March 8, 2024
Accepted:	March 11, 2024

---

*Editor: Artem Rogovskyy*

*Reviewer(s): Disclosure of reviewer identity is with reference to reviewer comments included in decision letter(s). The following individuals involved in review of your submission have agreed to reveal their identity: Kobra Mokhtarian (Reviewer #1)*

### Transaction Report:

(Note: With the exception of the correction of typographical or spelling errors that could be a source of ambiguity, letters and reports are not edited. The original formatting of letters and referee reports may not be reflected in this compilation.)

**DOI: <https://doi.org/10.1128/spectrum.00095-24>**

Re: Spectrum00095-24 (Diagnosis of anti-fasciolosis antibodies in Brazilian cattle through enzyme-linked immunosorbent assay (ELISA) employing both native and recombinant antigens)

Dear Dr. GUILHERME DRESCHER:

Thank you for the privilege of reviewing your work. Below you will find my comments, instructions from the Spectrum editorial office, and the reviewer comments.

Please return the manuscript within 60 days; if you cannot complete the modification within this time period, please contact me. If you do not wish to modify the manuscript and prefer to submit it to another journal, notify me immediately so that the manuscript may be formally withdrawn from consideration by Spectrum.

### Revision Guidelines

To submit your modified manuscript, log into the submission site at <https://spectrum.msubmit.net/cgi-bin/main.plex>. Go to Author Tasks and click the appropriate manuscript title to begin. The information you entered when you first submitted the paper will be displayed; update this as necessary. Note the following requirements:

- Upload point-by-point responses to the issues raised by the reviewers in a file named "Response to Reviewers," NOT IN YOUR COVER LETTER
- Upload a compare copy of the manuscript (without figures) as a "Marked-Up Manuscript" file
- Upload a clean .DOC/.DOCX version of the revised manuscript and remove the previous version
- Each figure must be uploaded as a separate, editable, high-resolution file (TIFF or EPS preferred), and any multipanel figures must be assembled into one file
- Any [supplemental material](#) intended for posting by ASM should be uploaded separate from the main manuscript; you can combine all supplemental material into one file (preferred) or split it into a maximum of 10 files, with all associated legends included

For complete guidelines on revision requirements, see our [Submission and Review Process](#) webpage. Submission of a paper that does not conform to guidelines may delay acceptance of your manuscript.

**Data availability:** ASM policy requires that data be available to the public upon online posting of the article, so please verify all links to sequence records, if present, and make sure that each number retrieves the full record of the data. If a new accession number is not linked or a link is broken, provide Spectrum production staff with the correct URL for the record. If the accession numbers for new data are not publicly accessible before the expected online posting of the article, publication may be delayed; please contact production staff ([Spectrum@asmusa.org](mailto:Spectrum@asmusa.org)) immediately with the expected release date.

**Publication Fees:** For information on publication fees and which article types are subject to charges, visit our [website](#). If your manuscript is accepted for publication and any fees apply, you will be contacted separately about payment during the production process; please follow the instructions in that e-mail. Arrangements for payment must be made before your article is published.

**ASM Membership:** Corresponding authors may [join or renew ASM membership](#) to obtain discounts on publication fees. Need to upgrade your membership level? Please contact Customer Service at [Service@asmusa.org](mailto:Service@asmusa.org).

The ASM Journals program strives for constant improvement in our submission and publication process. Please tell us how we can improve your experience by taking this quick [Author Survey](#).

Thank you for submitting your paper to Spectrum.

Sincerely,  
Artem Rogovskyy  
Editor  
Microbiology Spectrum

Reviewer #1 (Comments for the Author):

The following paragraph should be rewritten. The results show whether it is in the stool or in the serum. Please rewritten clearly. It is difficult to distinguish the eggs of Fasciola species by microscopic observation. How was the diagnosis made?

Reviewer #2 (Comments for the Author):

- The number of sample size is confusing, there are 500, 433 and 139. The number of samples should be the same or tallying.
2. The Number of positives should indicated and in brackets, you put the positive percentage eg 111/139 (80%) unlike only 80% or 0.80. This can be misleading to some readers.
  3. The Confidence interval should be recalculated, it is misleading or misreading. This is a range of 95% CI 80% (72-85%) OR 95% CI 0.80 (0.72-0.85) OR 95% CI 0.80 (0.72; 0.85)

1 **Diagnosis of anti-fasciolosis antibodies in Brazilian cattle through enzyme-linked**  
2 **immunosorbent assay (ELISA) employing both native and recombinant antigens**

3 Guilherme Drescher<sup>a\*</sup>, Hellen Geremias dos Santos<sup>b</sup>, Mariane Marques da Guarda  
4 Pinto<sup>a</sup>, Luis Gustavo Morello<sup>c,d</sup>, Fabiano Borges Figueiredo<sup>a</sup>

5  
6 <sup>a</sup> Cellular Biology Laboratory, Carlos Chagas Institute, Oswaldo Cruz Foundation  
7 (FIOCRUZ-PR), Curitiba 81310-020, Brazil.

8 <sup>b</sup> Carlos Chagas Institute, Oswaldo Cruz Foundation (FIOCRUZ-PR), Curitiba 81310-020,  
9 Brazil.

10 <sup>c</sup> Laboratory for Applied Science and Technology in Health, Carlos Chagas Institute,  
11 Oswaldo Cruz Foundation (FIOCRUZ-PR), Curitiba, 81310-020, Brazil.

12 <sup>d</sup> Parana Institute of Molecular Biology, Curitiba, 81310-020, Brazil.

13  
14 **\*Correspondence author:** Guilherme Drescher ([guidrescher@yahoo.com.br](mailto:guidrescher@yahoo.com.br)) and  
15 Fabiano Borges Figueiredo ([fabiano.figueiredo@fiocruz.br](mailto:fabiano.figueiredo@fiocruz.br)).

16  
17 Abstract

18  
19 Bovine fasciolosis is a parasitic disease with global reach. Coprological based on egg  
20 detection in fecal samples and liver inspection to evaluate the presence of the parasite is  
21 currently the gold standard for diagnosing **cattle fasciolosis**. However, these techniques  
22 are labor-intensive and ineffective during the acute phase of the disease. Serodiagnosis  
23 using native and recombinant antigens has become an interesting alternative in efforts to  
24 identify cattle fasciolosis. In the present study, we evaluated cattle from abattoirs through  
25 liver inspection and from farms through coprological examination. Our laboratory team  
26 optimized and validated an ELISA to detect serum anti-fasciolosis antibodies in cattle.  
27 This assay utilized native antigens, somatic antigen and excretory/secretory proteins, in  
28 addition to the recombinant antigen cathepsin L-1. The native antigens were derived from  
29 parasite, the recombinant antigen was produced in the laboratory. For animals from  
30 abattoirs, both *FhES* and *FhrCL-1* presented an area under the ROC curve of 0.80, with  
31 a sensitivity of 0.80, (95% CI 0.46; 0.95) and 0.70 (95% CI 0.38; 0.90) and specificity of  
32 0.81 (95% CI 0.73; 0.87) and 0.87 (95% CI 0.80; 0.92), respectively. *FhES* gave the best  
33 performance for those originating from the farm, with an AUROC of 0.84, sensitivity of  
34 0.79 (95%CI 0.60; 0.90), and specificity of 0.86 (95%CI 0.82; 0.89). In conclusion, our  
35 study highlights the potential of serodiagnosis for accurately screening cattle fasciolosis.  
36 When comparing liver inspection and coprological examination, the promising sensitivity  
37 and specificity values of *FhES* highlight its importance as a tool for cattle fasciolosis  
38 diagnosis.

39  
40  
41 Keywords: Fasciolosis, cattle, native antigens (*FhES* and *FhSA*), recombinant antigen  
42 (*FhrCL-1*), ELISA.

43  
44

45 *Introduction*

46

47 *Fasciola hepatica*, a plant-borne trematode species, is responsible for the zoonotic  
48 disease known as fasciolosis or liver fluke disease in humans and animals (1–3). The  
49 disease has traditionally been characterized as important in the veterinary context due to  
50 the substantial production and economic losses it causes in livestock (4–7). Herbivorous  
51 mammal hosts such as cattle, goats, and sheep are the most important disease  
52 transmission path to humans (8). Human fasciolosis is considered a neglected tropical  
53 disease by the World Health Organization (WHO), with estimates of 2.4 million infected  
54 individuals and 180 million people at risk of infection worldwide (9,10).

55 This trematode has an extensive global distribution and is found on every continent  
56 except Antarctica. Human fasciolosis poses major health problems in Europe, Cuba,  
57 Oceania, and the Americas (1,11), with a higher number of cases reported in South  
58 America (Bolivia, Peru, Chile, Ecuador, and Venezuela) than in other regions (3,12–14).  
59 In contrast, non-Andean, lowland countries in South America have reported sporadic and  
60 isolated human cases, including Uruguay (15) and Brazil (16,17). Among animals, studies  
61 in the Americas have demonstrated a wide prevalence in goats and a lower prevalence  
62 in cattle (18,19). In the Brazilian state of Santa Catarina, a prevalence of 10.8% in cattle  
63 was documented in an abattoir (20). Fasciolosis causes economic losses related to cattle  
64 production and severely impacts public health (6,20,21). Such economic losses have  
65 been quantified at a national level in Brazil, with a 5.8% reduction in carcass weight  
66 translating to a 35 USD loss per head in this country (22,23).

67 *Fasciola hepatica* is adaptable to different environmental conditions and has the  
68 ability to switch hosts (24), resulting in a broad host range (10). Its spread is also related  
69 to the geographic expansion of its original intermediate host, the Lymnaeidae snails (1).  
70 The life cycle of this disease comprises three stages, each characterized by distinct  
71 symptoms. The acute phase, initiated through ingestion of metacercariae in contaminated  
72 vegetation and water, lasts two to four months and manifests as abdominal pain, fever,  
73 urticaria, and gastrointestinal disturbances (2,25). The latent phase involves newly  
74 encysted juveniles penetrating the intestinal wall and peritoneum, migrating to the liver  
75 tissue, and reaching the bile ducts over several months (26–28). In the chronic phase,  
76 mature parasites in bile ducts produce eggs, causing severe liver and bile duct damage.

77 The established diagnostic method for bovine fasciolosis is the identification of  
78 eggs in feces (coprological examination), which is cost-effective and the gold standard  
79 for various parasitic diseases in humans and animals (27,29). Diagnosis throughout  
80 coprological examination often occurs during the chronic phase, when much of the liver  
81 damage has already occurred (28). However, there is a consensus that this method is not  
82 completely reliable for several reasons. A period of 8–15 weeks post-infection is required  
83 for *F. hepatica* eggs to appear in feces, when many pathological lesions have already  
84 manifested (30,31). Additionally, the method may not detect low-intensity or intermittent  
85 infections (27,32). In regions in which the disease is not endemic, infections with  
86 immature flukes are not detected. Furthermore, the eggs are released intermittently from  
87 the bile ducts, so stool samples from infected patients (humans and animals) may not  
88 contain eggs (27).

89 Post-mortem worm counting in the liver can be considered a valuable diagnostic  
90 method if the livers are appropriately sliced and soaked. *Fasciola hepatica* can also be

91 identified by inspecting cattle livers for adult worms in abattoirs. Postmortem examination  
92 of the bovine liver is a key approach to assessing the severity of *F. hepatica* infections.  
93 This entails examining livers for juvenile worms and bile ducts for adults, along with any  
94 associated pathological changes. Different rates of bovine fasciolosis have been reported  
95 in different abattoirs globally, with Brazil, for instance, documenting a 29.51% infection  
96 rate among animals (33). However, even mild or prepatent infections can evade  
97 detection, impacting the estimated sensitivity and specificity of the test.

98 Serological techniques, including lateral flow assays (34), and the indirect enzyme-  
99 linked immunosorbent assay (ELISA) (35–38), have been explored for detecting specific  
100 antibodies. ELISA-based detection of serum antibodies is a widely used diagnostic tool.  
101 It is highly regarded for its sensitivity and reliability in diagnosing acute infections, and it  
102 can complement fecal analysis for diagnosing latent and chronic infections (27). The  
103 antigens traditionally employed in serological tests consist of native antigens (somatic  
104 antigens and excretory/secretory antigens) of *F. hepatica* (35). To enhance diagnostic  
105 specificity, several purified *F. hepatica* antigens and recombinant antigens (36,37) have  
106 been used, most notably cathepsin L, a major protease involved in bovine fascioliasis.  
107 Serological tests have demonstrated high accuracy in diagnosing human, bovine, and  
108 ovine fasciolosis. The recombinant cathepsin L1 test utilizes recombinant pro-cathepsin  
109 L1 and targets antibodies against cathepsin, a cysteine protease, for diagnosing  
110 fasciolosis caused by *F. hepatica* (37,39), with no reported cross-reactions. Similarly,  
111 other studies observed no cross-reactions in native antigens and cathepsin-based ELISA  
112 tests, reporting strong performance (39–44). While many serological methods have been  
113 published, only a few have been commercially adopted.

114 In this context, the present study aimed to assess the potential of available native  
115 antigens, both somatic (*FhSA*) and excretory/secretory (*FhSE*), and the recombinant  
116 antigen cathepsin L (*FhrCL-1*) for serodiagnosis of **cattle fasciolosis in Brazil.**

## 117 *Materials and methods*

118  
119  
120 The protocols and methods used were approved by the Ethics Committee of the  
121 Evandro Chagas Institute (INI/FIOCRUZ) (protocol CAAE: 10324719.6.0000.5262).

### 122 *Characteristics of the cattle included in the study*

123  
124  
125 Five hundred serum and fecal samples (420 from females and 80 from males)  
126 were obtained from 37 cattle farms in southern Santa Catarina. The samples were  
127 collected from cattle ranging in age from six months to 20 years. Fecal samples (6g) were  
128 used for in vivo diagnostics of cattle fasciolosis through coprological examination based  
129 on a sedimentation protocol (32). The tests were conducted in triplicate, and the entire  
130 sediments were analyzed under a stereomicroscope (32,45).

131 **We found 405 negative and 95 positive results for eggs in the fecal samples. Of**  
132 **the 95 positive animals, 38 (7.6%) were positive for *F. hepatica*, 28 for *F. hepatica* eggs**  
133 **only, and 10 for *F. hepatica* and other parasites: seven also contained eggs of strongylid**  
134 **genera, two *Eimeria* eggs, and one Strongylidae and *Eimeria* eggs. The examination also**  
135 **showed that 44 (8.8%) cattle were positive for strongylid genera only and 13 (2.6%) for**  
136 **both strongylid genera and *Eimeria*. Animals positive for other parasites than *F. hepatica***

137 were excluded from the diagnostic performance evaluation of native and recombinant  
138 antigens.

139 A total of 139 serum samples were collected from a cattle abattoir located in  
140 southern Santa Catarina. The presence of cattle fasciolosis was determined through liver  
141 inspection. According to this approach, 10 (7.2%) cattle were diagnosed with *F. hepatica*,  
142 with no other parasites investigated during the veterinary inspection.

143 Serum samples collected from both the abattoir and farms were processed, divided  
144 into aliquots, and stored at -30°C for subsequent ELISA testing.

145

#### 146 *FhSA and FhES*

147

148 The *FhSA* and *FhES* preparations were carried out as follows: intact and live adult  
149 parasites were obtained from cattle livers at a local abattoir. Initially, the parasites  
150 underwent a series of 3–4 washes at room temperature using 0.01 M phosphate-buffered  
151 saline (PBS) with a pH of 7.2 to eliminate any traces of blood and bile.

152 For the *FhSA* preparation, the parasites were kept in a PBS solution and  
153 transported to the laboratory. Subsequently, the parasites were macerated and divided  
154 into separate portions. The protease inhibitor trans-Epoxy succinyl-L-leucylamido(4-  
155 guanidino) butane (E-64) (Sigma-Aldrich, US) was added to each sample at a  
156 concentration of 10 µM to minimize protein degradation. The antibiotics penicillin (100  
157 U/mL) and streptomycin (0.25 mg/mL) were also incorporated to counteract bacterial  
158 activity.

159 For the *FhES* preparation, parasites were incubated in Roswell Park Memorial  
160 Institute (RPMI) 1640 medium at 37°C for 6 h. Within the laboratory setting, the parasites  
161 were subjected to five washing rounds with PBS containing antibiotics (penicillin and  
162 streptomycin). The first two washes used a volume of 10 mL PBS with antibiotics, while  
163 the subsequent three used a volume of 8 mL. Subsequently, the parasites were  
164 transferred using forceps into a 15 mL falcon tube containing RPMI 1640 medium  
165 preheated to 37°C. They were then cultured at a concentration of six parasites per 3 mL  
166 for 6 h at 37°C.

167 After incubation, the falcon tube was centrifuged at 14,000g for 30 min. The  
168 supernatant was then collected and divided into three microtubes, each containing 1 mL.  
169 E-64 was introduced to prevent protein degradation. The secretory/excretory antigens  
170 were obtained by culturing *F. hepatica* in RPMI medium and filtered using an Amicon  
171 Ultra-15 100 kDa centrifugal filter (Millipore, UK). During the antigen filtration process from  
172 the excretory/secretory systems, the RPMI medium was replaced with a saline buffer.

173 Sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) was  
174 conducted to analyze the protein content within *FhSA* and *FhES*. Quantification of both  
175 the somatic antigen and the excretory/secretory antigens was carried out using a  
176 fluorimetric method in a Qubit® (Thermo Fischer Scientific, US) instrument. Following  
177 protein quantification, the supernatants of *FhSA* and *FhES* were divided into aliquots and  
178 stored at -30°C until use.

179

#### 180 *Expression and purification of FhrCL-1*

181



182 The full-length cDNA of *F. hepatica* preprocathepsin L1 (U62288.2) was obtained  
183 commercially in the pPIC9K vector from (GenScript, US). Protein expression was  
184 conducted using the multicopy system of the *Pichia pastoris* GS115 strain. The  
185 recombinant sequence featured a single amino acid substitution, replacing the active site  
186 Cys25 with Gly. This alteration resulted in the loss of functional activity while preserving  
187 the enzyme's conformation, rendering it more stable during fermentation and downstream  
188 isolation processes (39,46,47).

189 To generate the inactive enzyme, fermentation was performed in a liquid minimal  
190 medium containing yeast extract and glycerol (BMGY) to enhance yeast cell density.  
191 Cultivation in BMGY took place for 16 h at 30°C with agitation at 250 rpm. Once the yeast  
192 cell density reached an OD600 of 2–6, approximately 1 mL of the inoculum was  
193 transferred to a liquid minimal medium containing yeast extract and methanol (BMMY) to  
194 induce *FhrCL1* expression. Cultivation in BMMY lasted 92 h at 30°C under agitation at  
195 250 rpm. During this time, the medium was supplemented with 1% methanol every 24  
196 hours.

197 After completing the cultivation period, the culture was centrifuged at 10,000g for  
198 30 min at room temperature. The resulting pellets were discarded. *FhrCL-1* was isolated  
199 from the supernatant using Ni-NTA affinity chromatography, following previously  
200 described methods (39,47,48).

201

## 202 *ELISA optimization and development*

203

### 204 *FhSA, FhES, and FhrCL-1*

205

206 To define ELISA conditions, we performed a matrix comparison using various  
207 antigen concentrations, dilutions of the primary sera, and dilutions of secondary  
208 antibodies for *FhSA*, *FhES*, and *FhrCL-1* antigens, respectively.

209 Optimal antigen concentrations and serum dilutions were determined by  
210 checkerboard titrations. *FhSA*, *FhES*, and *FhrCL-1* antigens (0.5µg/mL, 1.0µg/mL, and  
211 1.0µg/mL, respectively) were dissolved separately in bicarbonate/carbonate coating  
212 buffer at pH 9.0 and added to each ELISA plate (Sarstedt AG & Co. KG, DE). One  
213 hundred microliters of the solution were then added to each well and incubated overnight  
214 at 4°C. The plates were washed three times with 0.05% Tween-80 in water. After coating,  
215 an additional blocking step with 100µL 1% skimmed milk in 0.05% Tween-80 was  
216 performed for 1 h at 37°C. After a further washing procedure, 100µL of sera-diluted pooled  
217 samples were added to each antigen (1:50, 1:100, and 1:50, respectively), and the plates  
218 were incubated for 1 h at 37°C. Following another wash, 100µL of peroxidase-conjugated  
219 anti-bovine antibody (Sigma-Aldrich, US) for each antigen (1:10.000, 1:10.000, and  
220 1:30.000, respectively) was added to the wells, and the plates were incubated for 30 min  
221 at 37°C. After a final washing step, bound antibodies were detected by adding 100µL of  
222 tetramethylbenzidine (TMB) (Thermo Fischer Scientific, US). The color was developed  
223 for 10 min, and the reaction was stopped with 50µL of 0.1 M sulfuric acid. The plates were  
224 read on an ELISA reader at 450nm to determine absorbance values.

225 After developing and optimizing serological ELISA conditions, we tested samples  
226 from cattle collected in an abattoir and cattle farms. Negative and positive controls were  
227 used to diagnose fasciolosis in cattle by ELISA, using *FhSA*, *FhES*, and *FhrCL-1* as



228 antigens. A pool of four samples (two negative samples for the presence of fasciolosis in  
229 the visceral inspection and two negative samples for the coprological examination) was  
230 used as a negative control on each plate. As a positive control, a pool of four samples  
231 was used on each plate (two positive samples for the presence of fasciolosis in the  
232 visceral inspection and two positive samples for the coprological examination). Positive  
233 control, negative control, and plate control were used in duplicate in all experiments.

234

### 235 *Statistical analysis*

236

237 To evaluate the diagnostic performance of native (*FhSA* and *FhES*) and  
238 recombinant antigens (*FhrCL-1*), we used liver inspection and coprological examination  
239 as the gold standard test for cattle from abattoirs and farms, respectively. Initially, the  
240 distribution of the quantitative values for the serodiagnosis tests was analyzed according  
241 to the categories (positive or negative) of the gold standard tests, aiming to explore their  
242 descriptive statistics, such as minimum, maximum, and median values, first and third  
243 quartile, mean values and standard deviation, as well as to inspect for outliers.

244 The optimal cutoff value for each ELISA method was based on a logistic regression  
245 model, considering as response variable the gold standard test results (positive or  
246 negative) and as predictor the quantitative values of the serodiagnosis test. Briefly, we  
247 applied a logistic regression model to adjust a classifier and a leave-one-out cross-  
248 validation (CV) technique to evaluate its diagnostic performance in data not used for its  
249 adjustment. Thus, on each CV iteration, the observations were randomly divided into  
250 training and test data; the former was used to adjust a logistic model and the latter to  
251 estimate the probability of being classified as a positive sample. After all samples were  
252 part of the training and test data, the vector of estimated probabilities was used to  
253 evaluate the diagnostic performance of the model. For this, it was necessary to choose a  
254 cutoff point for the estimated probability, aiming to classify samples as positive or  
255 negative. We chose the cutoff that maximizes the model's sensitivity and specificity and  
256 calculated the area under the receiver operating characteristic (AUCROC) curve,  
257 sensitivity (S), specificity (E), positive predictive values (PPV), and negative predictive  
258 values (NPV) and the respective 95% confidence intervals (CI) of all of these estimates.  
259 The analyses were performed on R using caret, pROC, and CompareTests packages.

260

### 261 *Results*

262

263 **Table 1 shows** a summary of the *FhES*, *FhSA*, and *FhrCL-1* values according to  
264 the presence (positive group) or absence (negative group) of fascioliasis detected by liver  
265 inspection of cattle from the abattoir (n=139). In general, for the three tests, the positive  
266 group had higher values for the first and third quartiles as well for median and mean than  
267 the negative group.

268

### 269 *Insert Table 1*

270

271 The AUROC for *FhES*, *FhSA*, and *FhrCL-1* adjusted models were 0.80 (95%CI:  
272 0.67; 0.92), 0.74 (95%CI: 0.55; 0.93) and 0.80 (95%CI: 0.61; 0.98), respectively (Figure  
273 1). For each test, we chose the cutoff point that maximizes the model's sensitivity and

274 specificity (Table 2). The three tests had a moderately accurate performance, although  
275 *FhES* showed higher sensitivity and NPV (0.80 and 0.98, respectively), indicating that the  
276 test is suitable for fasciolosis screening, as it had a low frequency of false negative results:  
277 two of approximately 10 cases of the disease were mistakenly classified as negative.  
278 Thus, out of 106 negative results, only two were false. Even though the specificity of the  
279 tests was high, the fact that the disease occurs rarely (7.2%) means that the tests cannot  
280 be used to confirm the presence of the disease due to the large number of false-positive  
281 results (for example, for *FhES*, 25 of 33 positive results were false).

282

### 283 ***Insert Table 2 and Figure 1***

284

285 Table 3 shows the summary values of *FhES*, *FhSA*, and *FhrCL-1* according to the  
286 presence (positive group) or absence (negative group) of fasciolosis detected by  
287 coprological examination in cattle from farms. The positive group had higher values for  
288 the first and third quartiles as well as for the median and mean for the three serological  
289 tests than the negative group.

290

### 291 ***Insert Table 3***

292

293 The AUROCs for *FhES*, *FhSA*, and *FhrCL-1* adjusted models were 0.84 (95%CI:  
294 0.76; 0.93), 0.73 (95%CI: 0.61; 0.85), and 0.67 (95%CI: 0.54; 0.80), respectively (Figure  
295 2). For each test, we chose the cutoff point that maximizes the model's sensitivity and  
296 specificity (Table 4). For this scenario, the *FhES* also presented better results, with a  
297 sensitivity of 0.79 and an NPV of 0.98. Of the 353 negative results, only six were false  
298 negatives when using the chosen cutoff value for the *FhES*. This confirms its suitability  
299 for screening fasciolosis. Despite the high specificity, the disease prevalence was only  
300 5.6%, out of the 80 positive results, and 58 were false positive results.

301

### 302 ***Insert Table 4 and Figure 2***

303

304 Aiming to investigate the impact of cross-reactions on the diagnostic performance  
305 of the three antigens (*FhES*, *FhSA*, and *FhrCL-1*), for the 95 positive samples (according  
306 to the coprological examination), we evaluated the distribution of absorbance values and  
307 the cut-off points obtained from the adjusted models that considered samples positive for  
308 fascioliasis only (Supplementary Figure 1). Overall, these results show that positive  
309 samples for fasciolosis had higher absorbance values. We also adjusted the logistic  
310 regression models by considering cattle samples from farms positive for parasitic  
311 infections other than fasciolosis (n=500). Supplementary Table 1 shows the summary  
312 values of *FhES*, *FhSA*, and *FhrCL-1* according to the presence (positive group) or  
313 absence (negative group) of fasciolosis and the Supplementary Table 2, the results of the  
314 adjusted models. The AUROC curve for the *FhES*, *FhSA*, and *FhrCL-1* were similar to  
315 those that considered only samples positive for fascioliasis: 0.83 (95%CI: 0.75; 0.90),  
316 0.73 (95%CI: 0.63; 0.83), and 0.68 (95%CI: 0.58; 0.79), respectively (Supplementary  
317 Figure 2).

318

319

320 *Discussion*

321

322 Our study is the first to compare native and recombinant antigens for diagnosing  
323 cattle fasciolosis in Brazilian animals. Coprological and liver inspection were used as the  
324 gold standard diagnostic tests for both farm and abattoir animals. The *FhES* serological  
325 test was better able to discriminate positive and negative samples for both farm and  
326 abattoir animals, and it seems suitable for screening purposes. The economic and public  
327 health problems caused by cattle fasciolosis have been reported in different parts of the  
328 world, including Brazil (20,21,28,49). It is important to develop and establish a reliable,  
329 simple, and rapid diagnostic tool for properly diagnosing cattle fasciolosis in Brazil,  
330 especially in endemic areas. In the present study, we evaluated the performance of three  
331 ELISA tests using *FhES*, *FhSA*, and *FhrCL-1* antigens to diagnose cattle fasciolosis  
332 based on information obtained from a meta-analysis study (50).

333 Liver necropsy, which diagnoses fasciolosis when bile ducts are dissected, is the  
334 only conclusive diagnostic procedure for *F. hepatica* (7,51). This is impractical as a herd  
335 or flock management tool, as it can only be carried out postmortem. Specific ELISA tests  
336 for liver flukes have been developed to meet these requirements and are now routinely  
337 used for cattle (30,52). ELISAs for *F. hepatica* are versatile tests capable of detecting  
338 specific antibodies or antigens in fecal samples as well as pooled or individual milk and  
339 sera (36,37,53). One significant drawback of relying on fecal egg counts is the inability to  
340 diagnose immature migrating stages of liver flukes within the final host. Consequently,  
341 using ELISA tests with early diagnostic potential represents a notable advantage (27,36).  
342 The most detrimental phase of this infection occurs during the migration of immature  
343 stages (36,37). The application of ELISA techniques for *F. hepatica* diagnosis has  
344 consistently exhibited enhanced sensitivity compared to coprological methods (36–38).  
345 Moreover, it offers the distinct advantage of detecting pre-patent infections.

346 Serological diagnosis of cattle fasciolosis based on fractions of adult worm  
347 antigens has been reported in different studies worldwide (36,43,54). To this end, we  
348 used two cattle populations with known infection status (the presence of eggs in the feces  
349 or parasites in the liver). Our first serological panel comprised more than 100 cattle  
350 samples collected in an abattoir. A small number of articles that evaluated the diagnosis  
351 of fasciolosis in cattle used samples collected in abattoirs (36). Our second serological  
352 panel consisted of 500 samples of blood and feces from cattle collected on farms. The  
353 studies that evaluated the serological diagnosis of bovine fasciolosis used small panels  
354 with up to 100 animals (43,54–56).

355 A critical point for evaluating a new immunodiagnostic test is to propose a cut-off  
356 point that properly discriminates between negative and positive samples. The absorbance  
357 values of *FhES*, *FhSA*, and *FhrCL-1* antigens tested had a good ability to distinguish  
358 between positive and negative samples in abattoir samples. Only the *FhES* antigen  
359 performed well in differentiating positive and negative cattle fasciolosis on serum samples  
360 collected on farms. Our investigation demonstrated that the absorbance values for the  
361 *FhES* antigen were comparable to those reported in other studies when sera from cattle  
362 with fasciolosis were examined using coprological testing as the gold standard (55).

363 Our study established a cut-off value for each proposed ELISA test based on  
364 positive and negative samples using liver inspection and coprological examination as the  
365 gold standard tests. The cut-off points for *FhES*, *FhSA*, and *FhrCL-1* were, respectively,

366 0.4895, 0.379, and 0.1050 for cattle from the abattoir, and 0.4105, 0.4830, and 0.1270  
367 for those from farms. The native antigens *FhES* and *FhSA* consist of a complex mixture  
368 of proteins, potentially leading to elevated absorbance values. In contrast, the  
369 recombinant antigen *FhrCL-1* is a single purified protein, which could account for the  
370 comparatively lower absorbance values observed. Different approaches are employed  
371 when developing ELISA tests for serological diagnosis of fasciolosis in cattle. The cut-off  
372 values reported by studies assessing one of these antigens vary, although they are often  
373 higher than those found in our analysis. Different methods based on the average  
374 absorbance value and the ROC curve are used in the ELISA tests created using native  
375 and recombinant antigens for the serological diagnosis of bovine fasciolosis (36–  
376 38,55,57).

377 Serology offers the advantage of earlier detection of infections in comparison to  
378 fecal egg detection. In addition, when compared to coprological methods, serological  
379 approaches, particularly the ELISA test, are very sensitive and specific. Since *F. hepatica*  
380 is the main cause of cattle fasciolosis, most of the studies related to the disease diagnosis  
381 focus on purified subunits from either *FhSA* or *FhES* (native antigens) of this parasite  
382 species (36,43,58,59). The cattle in this study come from farms in southern Santa  
383 Catarina, where the prevalence of the disease is considered low (20). Despite the  
384 observed low prevalence of the disease, the antigen *FhES* showed good diagnostic  
385 performance for both samples collected in the abattoir and farms, with sensitivities of 80%  
386 and 79% and specificities of 81% and 86%, respectively. Other studies that also used  
387 native antigens reported sensitivity ranging from 80 to 100% and specificity from 50 to  
388 100% for serological diagnosis of bovine fasciolosis (37,60).

389 Serological diagnosis for cattle fasciolosis using recombinant antigens (cathepsin  
390 and saposin) has been developed in the last years. Cathepsin is an important enzyme  
391 the parasite uses to elicit a humoral response in cattle as early as two weeks after  
392 infection (36,38). In our study, the antigen *FhrCL-1* presented diagnostic performance as  
393 good as those observed in *FhES* for abattoir cattle.

394 Sera samples from farm cattle infected with other parasites were used to evaluate  
395 the impact of cross-reactivity in our ELISA tests. Cross-reactivity analysis is fundamental  
396 since fasciolosis is a worldwide parasitic disease that can co-occur with other cattle  
397 parasitic diseases. Furthermore, current parasitological methods depend on the worker's  
398 expertise because *F. hepatica* eggs can be confused with eggs from other helminths.  
399 Therefore, a good diagnostic test needs to be able to distinguish between *Fasciola* and  
400 other parasitic diseases. We did not observe substantial differences between the adjusted  
401 models without and with positive samples for other parasites, which suggests that the test  
402 differentiated animals positive for fasciolosis from cattle samples with other parasites.

403 In our study, the cattle in the positive group had positive fecal egg counts or the  
404 presence of *F. hepatica* in the liver, indicating that each animal was currently infected.  
405 Diagnosis of this infection is usually based on coprological techniques. The intermittent  
406 nature of the eggs' evacuation through the feces was the reason for the low sensitivity of  
407 the coproscopy in detecting fasciolosis in cattle (31). Moreover, a prolonged pre-patent  
408 period of 8–15 weeks after the infection is required for the eggs to be shed in the feces  
409 (27,31). Compared to fecal egg counts, serology can detect infections 7–8 weeks earlier  
410 (36,37) and is considered a very sensitive method (61), but it does not distinguish  
411 between current and past infections. Results indicated that indirect ELISA using *FhES*

412 and *FhrCL-1* antigens could be an efficient and rapid diagnostic method for cattle  
413 fasciolosis compared to coprology. Therefore, using both methods together provided  
414 excellent information about the real infection situation. Of the three antigens (*FhSA*,  
415 *FhES*, and *FhrCL-1*) tested for the serological diagnosis of *F. hepatica* in cattle, the *FhES*  
416 presented satisfactory results in both scenarios, when compared to liver inspection in  
417 cattle from abattoir and to coprological examination in those from farms, suggesting it  
418 may be used for the development of ELISA tests for fasciolosis screening.

419

#### 420 *Conclusion*

421

422 We have developed three ELISAs utilizing two native antigens and one  
423 recombinant antigen for detecting *F. hepatica* antibodies. We validated these ELISAs  
424 using cattle serum samples collected from farms and an abattoir, considering coprological  
425 examination and liver inspection as gold standard tests, respectively. The ELISA test  
426 using *FhES* as an antigen had good diagnostic performance in the two scenarios (abattoir  
427 and farm) evaluated as a test for screening fasciolosis. Notably, the results were  
428 promising even in the face of the relatively low prevalence of cattle fasciolosis. The  
429 proposed ELISA test has the potential to be used in situations where it is more challenging  
430 to do a coprological investigation or examine the liver of cattle. These assays constitute  
431 a vital component of the immunodiagnostic toolkit that our laboratory is developing to  
432 improve the serodiagnosis of fasciolosis in Brazilian cattle. Recognizing that positive  
433 outcomes in antibody detection tests may not necessarily indicate ongoing infections but  
434 a history of exposure, we are actively exploring alternatives, such as an antigen detection  
435 ELISA using monoclonal antibodies. As a prospect, it is important to apply the test to  
436 more positive samples and also to explore cross-infection. Furthermore, ongoing  
437 research efforts are focused on adapting our in-house ELISA methods into more  
438 streamlined and dependable formats, such as immunochromatography or dot ELISA. This  
439 adaptation aims to facilitate potential commercialization and validation within Brazilian  
440 regions where the disease is endemic.

#### 441 *Conflict of Interest*

442 The authors declare that the research was conducted in the absence of any commercial or  
443 financial relationships that could be construed as a potential conflict of interest.

#### 444 *Author Contributions*

445 GD, LGM, and FBF: Study conception and design. GD: Conceptualization, methodology,  
446 manuscript writing, and drafting the manuscript. HG dos S: Data curation, meta-analysis, and  
447 manuscript reviewing. MM da GP: Manuscript reviewing. LGM: Manuscript reviewing. FBF:  
448 Manuscript writing, reviewing, and editing. LGM and FBF supervised the study. All authors  
449 contributed to the article and approved the submitted version.

#### 450 *Funding*

451 This study was supported by Fundação Oswaldo Cruz (FIOCRUZ).

452 *Acknowledgments*

453 The authors would like to thank the Fundação Osvaldo Cruz (FIOCRUZ-PR), Coordenação de  
454 Aperfeiçoamento de Pessoal de Nível Superior (CAPES), and Conselho Nacional de Pesquisa  
455 (CNPq) for the possibility of developing this research. We also thank the FIOCRUZ Network of  
456 Technological Platforms for providing access to the Integrative Structural Biology facility at the  
457 Carlos Chagas Institute, FIOCRUZ-PR. We thank Wagner Nagib for providing the figure design  
458 and Jaqueline de Oliveira Rosa for the plasmid design. The authors would like to thank the Centro  
459 Universitário Barriga Verde (UNIBAVE).

460

461 *References*

462

- 463 1 Mas-Coma MS, Valero MA, & Bargues MD. 2009. Chapter 2 *Fasciola*,  
464 Lymnaeids and Human Fascioliasis, with a Global Overview on Disease  
465 Transmission, Epidemiology, Evolutionary Genetics, Molecular Epidemiology and  
466 Control. *Adv Parasit* 69:41–146. [https://doi.org/10.1016/S0065-308X\(09\)69002-3](https://doi.org/10.1016/S0065-308X(09)69002-3)
- 467 2 Mas-Coma MS, Esteban JG, Bargues MD. 1999. Epidemiology of human  
468 fascioliasis: a review and proposed new classification. *Bull World Health Organ*  
469 77:340–346. PMID: 10327713 PMCID: PMC2557647
- 470 3 Mas-Coma MS, Bargues MD, & Valero MA 2005. Fascioliasis and other plant-  
471 borne trematode zoonoses. *Int J Parasitol* 35:1255–1278.  
472 <https://doi.org/10.1016/j.ijpara.2005.07.010>
- 473 4 Abdel-Fatah OR, Arafa WM, Wahba AA, El-Dakhly KM. 2022. Economic losses,  
474 morpho-molecular identification, and identity of *Fasciola* species recovered from  
475 Egypt. *J Parasit Dis* 46:1036–1046. <https://doi.org/10.1007/s12639-022-01526-x>
- 476 5 Arias-Pacheco C, Lucas JR, Rodríguez A, Córdoba D, Lux-Hoppe EG. 2020.  
477 Economic impact of the liver condemnation of cattle infected with *Fasciola*  
478 *hepatica* in the Peruvian Andes. *Trop Anim Health Prod* 52:1927–1932.  
479 <https://doi.org/10.1007/s11250-020-02211-y>
- 480 6 Hayward AD, Skuce PJ, McNeilly TN. 2021. The influence of liver fluke infection  
481 on production in sheep and cattle: a meta-analysis. *Int J Parasitol* 51:913–924.  
482 <https://doi.org/10.1016/j.ijpara.2021.02.006>
- 483 7 Mathewos M, Endale H, Kebamo M. 2023. Coprological and postmortem  
484 assessment and economic significance of bovine fasciolosis in cattle slaughtered  
485 at Tarcha Municipal Abattoir, Southern Ethiopia. *Parasite Epidemiol Control*  
486 22:1–9. <https://doi.org/10.1016/j.parepi.2023.e00316>
- 487 8 Dorny P, Praet N, Deckers N, Gabriel S. 2009. Emerging food-borne parasites.  
488 *Vet Parasitol* 163:196–206. <https://doi.org/10.1016/j.vetpar.2009.05.026>
- 489 9 Hotez PJ, Brindley PJ, Bethony JM, King CH, Pearce EJ, Jacobson J. 2008.  
490 Helminth infections: the great neglected tropical diseases. *J Clin Invest*  
491 118:1311–1321. <https://doi.org/10.1172/JCI34261>
- 492 10 Mas-Coma MS. 2005. Epidemiology of fascioliasis in human endemic areas. *J*  
493 *Helminthol* 79:207–216. <https://doi.org/10.1079/joh2005296>
- 494 11 Opio LG, Abdelfattah EM, Terry J, Odongo S, Okello E. 2021. Prevalence of  
495 fascioliasis and associated economic losses in cattle slaughtered at lira



- 496 municipality abattoir in northern Uganda. *Animals* 11:1–10.  
497 <https://doi.org/10.3390/ani11030681>
- 498 12 Liba JW, Atsanda NN, Francis MI. 2017 Economic loss from liver condemnation  
499 due to Fasciolosis in slaughtered ruminants in Maiduguri abattoir, Borno State,  
500 Nigeria. *J Adv Vet Anim Res* 4:65–70. <http://doi.org/10.5455/javar.2017.d192>
- 501 13 Ngcamphalala PI, Malatji MP, Mukaratirwa S. 2022. Geography and ecology of  
502 invasive *Pseudosuccinea columella* (Gastropoda: Lymnaeidae) and implications  
503 in the transmission of *Fasciola* species (Digenea: Fasciolidae) – a review. *J*  
504 *Helminthol* 96:1–18. <https://doi.org/10.1017/S0022149X21000717>
- 505 14 Keiser J, Utzinger J. 2005. Emerging foodborne trematodiasis. *Emerg Infect Dis*  
506 11:1507–1514. <http://doi.org/10.3201/eid1110.050614>
- 507 15 Bargues MD, Gayo V, Sanchis J, Artigas P, Khoubbane M, Birriel S, Mas-Coma  
508 S. 2017. DNA multigene characterization of *Fasciola hepatica* and *Lymnaea*  
509 *neotropica* and its fascioliasis transmission capacity in Uruguay, with historical  
510 correlation, human report review and infection risk analysis. *PLoS Negl Trop Dis*  
511 11:1–33. <https://doi.org/10.1371/journal.pntd.0005352>
- 512 16 Igreja RP, Barreto MG, Soares Mda S. 2004. Fascioliasis: report of two cases  
513 from rural areas of Rio de Janeiro. *Rev Soc Bras Med Trop* 37:416–417.  
514 <https://doi.org/10.1590/s0037-86822004000500010>
- 515 17 Pritsch IC, Garcia RL, Douat D, Schwendler RR, Buttendorf MRB, Molento MB.  
516 2019. First reported case of clinical fascioliasis in Santa Catarina, Brazil. *Rev*  
517 *Soc Bras Med Trop* 52:5–7. <https://doi.org/10.1590/0037-8682-0070-2019>
- 518 18 Mas-Coma MS, Buchon P, Funatsu IR, Angles R, Artigas P, Valero MA, Bargues  
519 MD. 2020. Sheep and Cattle Reservoirs in the Highest Human Fascioliasis  
520 Hyperendemic Area: Experimental Transmission Capacity, Field Epidemiology,  
521 and Control Within a One Health Initiative in Bolivia. *Front Vet Sci* 7:1–14.  
522 <https://doi.org/10.3389/fvets.2020.583204>
- 523 19 Diaz-Quevedo C, Frias H, Cahuana GM, Tapia-Limonchi R, Chenet SM, Tejado  
524 JR. 2021. High prevalence and risk factors of fascioliasis in cattle in Amazonas,  
525 Peru. *Parasitol Int* 85: 1–6. <https://doi.org/10.1016/j.parint.2021.102428>
- 526 20 Fonseca e Albuquerque RB da, Pereira SA, de Melo SN, Belo VS, de Arruda  
527 MM, Mazetto D, Figueiredo, FB. 2022. Spatial distribution analysis of bovine  
528 fascioliasis cases recorded in an abattoir in the state of Santa Catarina, Brazil.  
529 *Cienc Rural* 52: 1–8. <https://doi.org/10.1590/0103-8478cr20210030>
- 530 21 Américo L, Padilha MAC, Arruda PM, Drescher G, de Moura AB, Chryssafidis  
531 AL. 2022. Epidemiological Survey and Confirmation of Autochthonous Cases of  
532 Bovine Fasciolosis in the Serrana Mesoregion of Santa Catarina, Brazil. *Front*  
533 *Vet Sci* 9:1–8. <https://doi.org/10.3389/fvets.2022.933462>
- 534 22 Mehmood K, Zhang H, Sabir AJ, Abbas RZ, Ijaz M, Durrani AZ, Saleem MH, Ur  
535 Rehman M, Iqbal MK, Wang Y, Ahmad HI, Abbas T, Hussain R, Ghori MT, Ali S,  
536 Khan AU, Li J. 2017. A review on epidemiology, global prevalence and  
537 economical losses of fasciolosis in ruminants. *Microb Pathog* 109:253–262.  
538 <https://doi.org/10.1016/j.micpath.2017.06.006>



- 539 23 Pritsch IC, Molento MB. 2018. Recount of Reported Cases of Human Fascioliasis  
540 in Brazil Over the Last 60 Years. *Rev Patol Trop* 47:75–85.  
541 <https://doi.org/10.5216/rpt.v47i2.53636>
- 542 24 Robinson MW, Dalton JP. 2009. Zoonotic helminth infections with particular  
543 emphasis on fasciolosis and other trematodiasis. *Philos Trans R Soc Lond B*  
544 *Biol Sci.* 364:2763–2776. <https://doi.org/10.1098/rstb.2009.0089>
- 545 25 Saba R, Korkmaz M, Inan D, Mamikoğlu L, Turhan O, Günseren F, Cevikol C,  
546 Kabaalioglu A. 2004. Human fascioliasis. *Clin Microbiol Infect* 10:385–387.  
547 <https://doi.org/10.1111/j.1469-0691.2004.00820.x>
- 548 26 Fica A, Dabanch J, Farias C, Castro M, Jercic MI, Weitzel T. 2012. Acute  
549 fascioliasis--clinical and epidemiological features of four patients in Chile. *Clin*  
550 *Microbiol Infect* 18:91–96. <https://doi.org/10.1111/j.1469-0691.2011.03575.x>
- 551 27 Mas-Coma MS, Bargues MD, Valero MA. 2014. Diagnosis of human fascioliasis  
552 by stool and blood techniques: update for the present global scenario. *Parasitol*  
553 141:1918–1946. <https://doi.org/10.1017/S0031182014000869>
- 554 28 Mas-Coma MS, Valero MA, Bargues MD. 2014. Fascioliasis. *Adv Exp Med Biol*  
555 766:77–114. [https://doi.org/10.1007/978-1-4939-0915-5\\_4](https://doi.org/10.1007/978-1-4939-0915-5_4)
- 556 29 Zárate-Rendón DA, Vlaminck J, Levecke B, Briones-Montero A, Geldhof P. 2019.  
557 Comparison of Kato-Katz Thick Smear, Mini-FLOTAC, and Flukefinder for the  
558 Detection and Quantification of *Fasciola hepatica* Eggs in Artificially Spiked  
559 Human Stool. *Am J Trop Med Hyg* 101:59–61. <https://doi.org/10.4269/ajtmh.18-0988>
- 560 30 Adamu M, Wossene A, Tilahun G, Basu AK. 2019. Comparative diagnostic  
561 techniques in ruminant Fasciolosis: fecal sedimentation, indirect ELISA, liver  
562 inspection and serum enzyme activities. *Ethiop Vet J* 23:42–58.  
563 <https://dx.doi.org/10.4314/evj.v23i1.4>
- 564 31 Alvarez Rojas CA, Jex AR, Gasser RB, Scheerlinck JP. 2014. Techniques for the  
565 diagnosis of *Fasciola* infections in animals: room for improvement. *Adv Parasitol*  
566 85:65-107. <https://doi.org/10.1016/B978-0-12-800182-0.00002-7>
- 567 32 Hoffman WA, Pons JA, Janer JJ. 1934. The Sedimentation Concentration  
568 Method in *Schistosomiasis Mansoni*. *PR J Public Health Trop Med* 9:281–298.
- 569 33 Dutra LH, Molento MB, Naumann CR, Biondo AW, Fortes FS, Savio D, Malone  
570 JB. 2010. Mapping risk of bovine fasciolosis in the south of Brazil using  
571 Geographic Information Systems. *Vet Parasitol* 169:76-81.  
572 <https://doi.org/10.1016/j.vetpar.2009.12.015>
- 573 34 Martínez-Sernández V, Muiño L, Perteguer MJ, Gárate T, Mezo M, González-  
574 Warleta M, Muro A, Correia da Costa JM, Romarís F, Ubeira FM. 2011.  
575 Development and evaluation of a new lateral flow immunoassay for  
576 serodiagnosis of human fasciolosis. *PLoS Negl Trop Dis* 11:1–7.  
577 <https://doi.org/10.1371/journal.pntd.0001376>
- 578 35 Arias M, Morrondo P, Hillyer GV, Sánchez-Andrade R, Suárez JL, Lomba C,  
579 Pedreira J, Díaz P, Díez-Baños P, Paz-Silva A. 2007. Immunodiagnosis of  
580 current fasciolosis in sheep naturally exposed to *Fasciola hepatica* by using a 2.9  
581

- 582 kDa recombinant protein. *Vet Parasitol* 146:46-49.  
583 <https://doi.org/10.1016/j.vetpar.2007.02.007>
- 584 36 Kuerpick B, Schnieder T, Strube C. 2013. Evaluation of a recombinant cathepsin  
585 L1 ELISA and comparison with the Pourquier and ES ELISA for the detection of  
586 antibodies against *Fasciola hepatica*. *Vet Parasitol* 193:206–213.  
587 <https://doi.org/10.1016/j.vetpar.2012.11.021>
- 588 37 Martínez-Sernández V, Perteguer MJ, Hernández-González A, Mezo M,  
589 González-Warleta M, Orbegozo-Medina RA, Romarís F, Paniagua E, Gárate T,  
590 Ubeira FM. 2018. Comparison of recombinant cathepsins L1, L2, and L5 as  
591 ELISA targets for serodiagnosis of bovine and ovine fascioliasis. *Parasitol Res*  
592 117:1521 – 1534. <https://doi.org/10.1007/s00436-018-5809-7>
- 593 38 Cornelissen JB, Gaasenbeek CP, Borgsteede FH, Holland WG, Harmsen MM,  
594 Boersma WJ. 2001. Early immunodiagnosis of fasciolosis in ruminants using  
595 recombinant *Fasciola hepatica* cathepsin L-like protease. *Int J Parasitol* 31:728–  
596 737. [https://doi.org/10.1016/s0020-7519\(01\)00175-8](https://doi.org/10.1016/s0020-7519(01)00175-8)
- 597 39 Gonzales Santana B, Dalton JP, Vasquez Camargo F, Parkinson M, Ndao M.  
598 2013. The diagnosis of human fascioliasis by enzyme-linked immunosorbent  
599 assay (ELISA) using recombinant cathepsin L protease. *PLoS Negl Trop Dis*  
600 7:1–9. <https://doi.org/10.1371/journal.pntd.0002414>
- 601 40 Espinoza JR, Maco V, Marcos L, Saez S, Neyra V, Terashima A, Samalvides F,  
602 Gotuzzo E, Chavarry E, Huaman MC, Bargues MD, Valero MA, Mas-Coma S.  
603 2007. Evaluation of Fas2-ELISA for the serological detection of *Fasciola hepatica*  
604 infection in humans. *Am J Trop Med Hyg* 76:977–982. PMID: 17488926
- 605 41 Rokni MB, Massoud J, O'Neill SM, Parkinson M, Dalton JP. 2002. Diagnosis of  
606 human fasciolosis in the Gilan province of Northern Iran: application of cathepsin  
607 L-ELISA. *Diagn Microbiol Infect Dis* 44:175–179. [https://doi.org/10.1016/s0732-8893\(02\)00431-5](https://doi.org/10.1016/s0732-8893(02)00431-5)
- 608
- 609 42 Aguayo V, Valdes B, Espino AM. 2018. Assessment of *Fasciola hepatica*  
610 glutathione S-transferase as an antigen for serodiagnosis of human chronic  
611 fascioliasis. *Acta Trop* 186:41–49.  
612 <https://doi.org/10.1016/j.actatropica.2018.07.002>
- 613 43 Mufti S, Afshan K, Khan IA, Irum S, Qureshi IZ, Rizvi SSR, Mukhtar M, Mushtaq  
614 M, Iqbal Z, Qayyum M. 2015. Serological and coprological studies of bovine  
615 fasciolosis in the Pothwar Region, Pakistan. *Pak Vet J* 35:178–182.
- 616 44 Gottstein B, Schneeberger M, Boubaker G, Merkle B, Huber C, Spiliotis M, Müller  
617 N, Garate T, Doherr MG. 2014. Comparative assessment of ELISAs using  
618 recombinant saposin-like protein 2 and recombinant cathepsin L-1 from *Fasciola*  
619 *hepatica* for the serodiagnosis of human Fasciolosis. *PLoS Negl Trop Dis* 8:1–  
620 10. <https://doi.org/10.1371/journal.pntd.0002860>
- 621 45 Charlier J, De Meulemeester L, Claerebout E, Williams D, Vercruyse J. 2008.  
622 Qualitative and quantitative evaluation of coprological and serological techniques  
623 for the diagnosis of fasciolosis in cattle. *Vet Parasitol* 153:44-51.  
624 <https://doi.org/10.1016/j.vetpar.2008.01.035>

- 625 46 Collins PR, Stack CM, O'Neill SM, Doyle S, Ryan T, Brennan GP, Mousley A,  
626 Stewart M, Maule AG, Dalton JP, Donnelly S. 2004. Cathepsin L1, the major  
627 protease involved in liver fluke (*Fasciola hepatica*) virulence: propetide cleavage  
628 sites and autoactivation of the zymogen secreted from gastrodermal cells. J Biol  
629 Chem 279:17038–17046. <https://doi.org/10.1074/jbc.M308831200>
- 630 47 O'Neill SM, Parkinson M, Strauss W, Angles R, Dalton JP. 1998.  
631 Immunodiagnosis of *Fasciola hepatica* infection (fascioliasis) in a human  
632 population in the Bolivian Altiplano using purified cathepsin L cysteine  
633 proteinase. Am J Trop Med Hyg 58:417–423.  
634 <https://doi.org/10.4269/ajtmh.1998.58.417>
- 635 48 O'Neill SM, Parkinson M, Dowd AJ, Strauss W, Angles R, Dalton JP. 1999. Short  
636 report: Immunodiagnosis of human fascioliasis using recombinant *Fasciola*  
637 *hepatica* cathepsin L1 cysteine proteinase. Am J Trop Med Hyg 60:749–751.  
638 <https://doi.org/10.4269/ajtmh.1999.60.749>
- 639 49 Barbosa R, Pinto C, Garcia P, Rodrigues A. Prevalence of fasciolosis in  
640 slaughtered dairy cattle from São Miguel Island, Azores, Portugal. 2019. Vet  
641 Parasitol Reg Stud Reports 17:1–6. <https://doi.org/10.1016/j.vprsr.2019.100319>
- 642 50 Drescher G, de Vasconcelos TCB, Belo VS, Pinto MMDG, Rosa JO, Morello LG,  
643 Figueiredo FB. 2023. Serological diagnosis of fasciolosis (*Fasciola hepatica*) in  
644 humans, cattle, and sheep: a meta-analysis. Front Vet Sci 10:1–13.  
645 <https://doi.org/10.3389/fvets.2023.1252454>
- 646 51 Owen H, Jones E, Kowald C, Hand S, McGowan M, Cobbold R, Barnes TS,  
647 Gibson JS, Ranjbar S, Palmieri C, Allavena R. 2023. Development and  
648 application of a new liver pathology recording system for use in cattle abattoirs.  
649 Res Vet Sci 158:164–184. <https://doi.org/10.1016/j.rvsc.2023.03.002>
- 650 52 Walsh TR, Ainsworth S, Armstrong S, Hodgkinson J, Williams D. 2021.  
651 Differences in the antibody response to adult *Fasciola hepatica*  
652 excretory/secretory products in experimentally and naturally infected cattle and  
653 sheep. Vet Parasitol 289:1–14. <https://doi.org/10.1016/j.vetpar.2020.109321>
- 654 53 Munita MP, Rea R, Martinez-Ibeas AM, Byrne N, Kennedy A, Sekiya M, Mulcahy  
655 G, Sayers R. 2021. Comparison of four commercially available ELISA kits for  
656 diagnosis of *Fasciola hepatica* in Irish cattle. BMC Vet Res 15:1–12.  
657 <https://doi.org/10.1186/s12917-019-2160-x>
- 658 54 Şimşek S, Köroğlu E, Ütük AE, Altay K. 2006. Use of indirect excretory/secretory  
659 enzyme-linked immunosorbent assay (ES-ELISA) for the diagnosis of natural  
660 *Fasciola hepatica* infection in eosinophilic and non-eosinophilic cattle from  
661 eastern Turkey. Turk J Vet Anim Sci 30:411–415.  
662 <https://journals.tubitak.gov.tr/veterinary/vol30/iss4/10>
- 663 55 Hillyer GV, Soler de Galanes M, Buchón P, Bjorland J. 1996. Herd evaluation by  
664 enzyme-linked immunosorbent assay for the determination of *Fasciola hepatica*  
665 infection in sheep and cattle from the Altiplano of Bolivia. Vet Parasitol 6:211–  
666 220. [https://doi.org/10.1016/0304-4017\(95\)00831-4](https://doi.org/10.1016/0304-4017(95)00831-4)

- 667 56 Salimi-Bejestani MR, Cripps P, Williams DJ. 2008. Evaluation of an ELISA to  
668 assess the intensity of *Fasciola hepatica* infection in cattle. *Vet Rec* 162:109 –  
669 111. <https://doi.org/10.1136/vr.162.4.109>
- 670 57 Cornelissen JB, Gaasenbeek CP, Boersma W, Borgsteede FH, van Milligen FJ.  
671 1999. Use of a pre-selected epitope of cathepsin-L1 in a highly specific peptide-  
672 based immunoassay for the diagnosis of *Fasciola hepatica* infections in cattle. *Int*  
673 *J Parasitol* 29:685–896. [https://doi.org/10.1016/s0020-7519\(99\)00017-x](https://doi.org/10.1016/s0020-7519(99)00017-x)
- 674 58 Kooshan M, Hashemi T, Naghibi A. 2010. Use of somatic and excretory-  
675 secretory antigens of *Fasciola hepatica* in diagnosis of sheep by ELISA. *Am-*  
676 *Eurasian J Agric Environ Sci* 7:170–175.
- 677 59 Heidari H, Zahiri H, Gharekhani J, Hosseini A, Aeineh S. 2015. Comparison of  
678 dot-ELISA and ELISA techniques for detection of *Fasciola hepatica* in sheep  
679 using excretory-secretory antigens. *Istanbul Univ Vet Fak Derg* 41:21–25.  
680 <https://doi.org/10.16988/iuvfd.2015.14154>
- 681 60 Mezo M, González-Warleta M, Ubeira FM. 2003. Optimized serodiagnosis of  
682 sheep fascioliasis by Fast-D protein liquid chromatography fractionation of  
683 *Fasciola hepatica* excretory-secretory antigens. *J Parasitol* 89:843–849.  
684 <https://doi.org/10.1645/GE-74R1.1>
- 685 61 Charlier J, Vercruysse J, Morgan E, van Dijk J, Williams DJ. 2014. Recent  
686 advances in the diagnosis, impact on production and prediction of *Fasciola*  
687 *hepatica* in cattle. *Parasitol* 141:326–335.  
688 <https://doi.org/10.1017/S0031182013001662>

**Table 1.** Descriptive summary for the three tests when applied to cattle from abattoirs (n=139).

	<b>Native antigens</b>		<b>Recombinant antigen</b>
<b>Summary values</b>	<i>FhES</i>	<i>FhSA</i>	<i>FhrCL-1</i>
<b>Positive group (n= 10)</b>			
Minimum	0.360	0.196	0.076
1st quartile	0.490	0.270	0.111
Median	0.571	0.443	0.252
Mean (SD)	0.573 (0.141)	0.439 (0.186)	0.235 (0.126)
2nd quartile	0.668	0.568	0.336
Maximum	0.815	0.716	0.436
<b>Negative group (n= 129)</b>			
Minimum	0.192	0.114	0.057
1st quartile	0.298	0.169	0.078
Median	0.362	0.222	0.090
Mean (SD)	0.393 (0.133)	0.263 (0.144)	0.104 (0.064)
2nd quartile	0.452	0.303	0.107
Maximum	0.806	1.247	0.638

Legend: SD= Standard Deviation.

**Table 2.** Diagnostic performance measures for the three tests by considering the presence of the parasite in the liver as the gold standard method (n=139).

	<b>Native antigens</b>		<b>Recombinant antigen</b>
<b>Performance measures</b>	<i>FhES</i> estimate (95%CI)	<i>FhSA</i> estimate (95%CI)	<i>FhrCL-1</i> estimate (95%CI)
Cutoff	0.4895	0.379	0.1050
Sensitivity	0.80 (0.46; 0.95)	0.70 (0.38; 0.90)	0.70 (0.38; 0.90)
Specificity	0.81 (0.73; 0.87)	0.86 (0.81; 0.92)	0.87 (0.80; 0.92)
PPV	0.24 (0.17; 0.34)	0.30 (0.19; 0.45)	0.29 (0.18; 0.43)
NPV	0.98 (0.94; 0.99)	0.97 (0.94; 0.99)	0.97 (0.94; 0.99)

Legend: CI= confidence intervals; PPV= positive predictive values; NPV= negative predictive values.

**Table 3.** Descriptive summary for the three tests when applied to cattle from farms (n=433).

	<b>Native antigens</b>		<b>Recombinant antigen</b>
<b>Summary values</b>	<i>FhES</i>	<i>FhSA</i>	<i>FhrCL-1</i>
<b>Positive group (n= 28)</b>			
Minimum	0.213	0.168	0.058
1st quartile	0.412	0.440	0.102
Median	0.529	0.637	0.141
Mean (SD)	0.560 (0.213)	0.641 (0.299)	0.184 (0.116)
2nd quartile	0.776	0.927	0.248
Maximum	0.828	1.312	0.454
<b>Negative group (n= 405)</b>			
Minimum	0.085	0.078	0.054
1st quartile	0.202	0.266	0.088
Median	0.259	0.382	0.103
Mean (SD)	0.289 (0.122)	0.406 (0.191)	0.113 (0.044)
2nd quartile	0.353	0.510	0.126
Maximum	0.898	1.373	0.410


Legend: SD= Standard Deviation.

**Table 4.** Diagnostic performance measures for the three tests by considering the coprological examination as the gold standard method (n=433).

	<b>Native antigens</b>		<b>Recombinant antigen</b>
<b>Performance measures</b>	<i>FhES</i> estimate (95%CI)	<i>FhSA</i> estimate (95%CI)	<i>FhrCL-1</i> estimate (95%CI)
Cutoff	0.4105	0.4830	0.1270
Sensitivity	0.79 (0.60; 0.90)	0.71 (0.52; 0.85)	0.57 (0.39; 0.74)
Specificity	0.86 (0.82; 0.89)	0.70 (0.66; 0.75)	0.75 (0.71; 0.79)
PPV	0.28 (0.22; 0.34)	0.14 (0.11; 0.18)	0.14 (0.10; 0.19)
NPV	0.98 (0.97; 0.99)	0.97 (0.95; 0.98)	0.96 (0.94; 0.97)


Legend: CI= confidence intervals; PPV= positive predictive values; NPV= negative predictive values.

**Figure 1.** ROC curves for FhES, FhSA and FhrCL-1 for cattle from abattoirs (n=139)





**Figure 2.** ROC curves for FhES, FhSA and FhrCL-1 for cattle from farms (n=433)



Reviewer's comments

	Line number	Current	Suggestion or Comments	Reasons
1	1	<b>Diagnosis of anti-fasciolosis antibodies in Brazilian cattle through enzyme-linked immunosorbent assay (ELISA) employing both native and recombinant antigens</b>	<b>Diagnosis of fasciolosis in Brazilian cattle through enzyme-linked immunosorbent assay (ELISA) employing both native and recombinant antigens”</b>	The title should change because we are detecting the disease using antibodies through ELISA ( <b>serological technique</b> ), hence we cannot say diagnosis of anti-fasciolosis antibodies.
2	24-25	In the present study, we evaluated cattle from abattoirs through liver inspection and from farms through coprological examination.	<b>In the present study, we evaluated cattle from abattoirs and farms through liver inspection and coprological examination respectively</b>	Repetition of wording
3	Abstract	ROC curve of 0.80, with a sensitivity of 0.80, (95% CI 0.46; 0.95) and 0.70 (95% CI 0.38; 0.90)	ROC curve of 0.80, with a sensitivity of 0.80, (95% CI 0.46- 0.95) and 0.70 (95% CI 0.38- 0.90) OR ROC curve of 0.80, with a sensitivity of 0.80, (95% CI 0.46, 0.95) and 0.70 (95% CI 0.38, 0.90)	The CI should be written as a range. However, check this range it's too big from 46% to 95% the other one from 38% to 90%
	66	....translating to a 35 USD loss per head in this country	.....translating to a 35 USD loss per <b>animal</b> in this country	Per head may be confusing to other readers.
	85	In regions in which the disease is not endemic, infections.....	In regions, <b>where</b> the disease is not endemic, infections....	
	106	bovine fascioliasis	Bovine fasciolosis	Be consistent
	125	500 samples	How did the authors come up with this samples size? Any sample size formula?	
	127	collected from cattle ranging in age from six months to 20 years.	...collected from cattle ranging from six months to 20 years old	
	131-142	We found 405 negative and 95 positive results for eggs in the fecal samples. Of 132 the 95 positive animals, 38 (7.6%) were positive for <i>F. hepatica</i> , 28 for <i>F. hepatica</i> eggs only, and 10	Move to results section	Because this section is for methodology only and not results.

		<p>for <i>F. hepatica</i> and other parasites: seven also contained eggs of strongylid genera, two <i>Eimeria</i> eggs, and one Strongylidae and <i>Eimeria</i> eggs. The examination also showed that 44 (8.8%) cattle were positive for strongylid genera only and 13 (2.6%) for both strongylid genera and <i>Eimeria</i>. Animals positive for other parasites than <i>F. hepatica</i> were excluded from the diagnostic performance evaluation of native and recombinant antigens. A total of 139 serum samples were collected from a cattle abattoir located in southern Santa Catarina. The presence of cattle fasciolosis was determined through liver inspection. According to this approach, 10 (7.2%) cattle were diagnosed with <i>F. hepatica</i>, with no other parasites investigated during the veterinary inspection.</p>		
	131	38 were positive for <i>F. hepatica</i>	Were the 38 included in the 139?	
	Table 2	0.80 (0.46; 0.95), 0.70 (0.38; 0.90), 0.70 (0.38; 0.90)	Recalculate all the ranges of CI, For example 0.80 (0.72-0.85); 0.7 (0.62-0.77) Also include the positive figures unlike only percentage positivity 80% of 139 is 111/139 (80%)	They look to be too wide and appears to be out of range, considering (n=139)
	Table 4	0.79(0.60;0.90)	Recalculate all the ranges of CI, e.g (0.79 (0.75-0.82	Some of them look to be too wide and appears to be out of range, considering (n=433)
		The number of samples differ. You have 500 in initial stage but you are reporting 433	The samples collected should all be analysed. Where are other 67 samples?	
		Only 139 serum and 500 fecal samples	For serum samples you analysed only 139 why not	

			analysed serum from all 500 animals so that you compare the results for feacal examination and serology results?	
	143	Serum samples collected from both the abattoir and farms were processed, divided into aliquots, and stored at -30°C for subsequent ELISA testing.	This suggest that you had 500 serum samples why conduct ELISA on 139 only?	

Generally the research is okay but needs major revision. The number samples are confusing there 500 then 433 and 139. The number of samples should the same or tallying.

2. The Number of positive should indicated and in brackets you put the positive percentage eg 111/139 (80%) unlike only 80% or 0.80. This can be misleading to some readers.

3. The Confidence interval should be recalculated it is misleading or misreading. This is a range 95% CI 80% (72-85%) OR 95% CI 0.80 (0.72-0.85) OR 95% CI 0.80 (0.72; 0.85)

We thank the reviewer for their helpful suggestions that improved the message of our manuscript. Please find in below our point-to-point answers and commentaries on some text improvements we have made. In the revised version of our manuscript, major changes/insertions are outlined in red.

Independent Review Report, Reviewer 2

1. Line 1. **Current:** “Diagnosis of anti-fasciolosis antibodies in Brazilian cattle through enzyme-linked immunosorbent assay (ELISA) employing both native and recombinant antigens”/ **Suggestion:** “Diagnosis of fasciolosis in Brazilian cattle through enzyme-linked immunosorbent assay (ELISA) employing both native and recombinant antigens.”

**RESPONSE:** thank you for mentioning this. We modified the title as suggested by the Reviewer.

2. Lines 24–25. **Current:** “In the present study, we evaluated cattle from abattoirs through liver inspection and from farms through coprological examination”/ **Suggestion:** “In the present study, we evaluated cattle from abattoirs and farms through liver inspection and coprological examination respectively.”

**RESPONSE:** we appreciate this comment. The text was rewritten as suggested by the Reviewer.

3. Abstract. **Current:** “ROC curve of 0.80, with a sensitivity of 0.80 (95% CI 0.46; 0.95) and 0.70 (95% CI 0.38; 0.90)”/ **Suggestion:** “ROC curve of 0.80, with a sensitivity of 0.80, (95% CI 0.46- 0.95) and 0.70 (95% CI 0.38- 0.90).” **Comment:** The CI should be written as a range. However, check this range it’s too big from 46% to 95% the other one from 38% to 90%.

**RESPONSE:** thank you for mentioning this. We modified de CI written as suggested by the Reviewer. Regarding the reviewer's observation about the size of the confidence interval (very large), we reviewed the analyzes performed and confirmed the values obtained. For the confidence interval estimation, we user CompareTests() function from CompareTests R package. In the current version of the manuscript, we include a link to an open access repository where the script used in data analysis was made available. These results are for the analyzes of abattoir data that includes 139 animals, of which 10 were positive for fasciolosis according to liver inspection. As the sample is small and the prevalence of the disease is low, we expected a wider (less precise) confidence interval, especially for the sensitivity measure. To aid in the interpretation of the performance measures presented, in the current version of our manuscript we highlight the sample size and the number of positive cases in the abstract and in the results section for each group we studied.

4. Line 66. **Current:** “...translating to a 35 USD loss per head in this country”/ **Suggestion:** “...translating to a 35 USD loss per animal in this country.”

**RESPONSE:** thank you for pointing this out. The sentence was rewritten as suggested by the Reviewer.

5. Line 85. **Current:** “In regions in which the disease is not endemic, infections...”/  
**Suggestion:** “In regions, where the disease is not endemic, infections....”

**RESPONSE:** thank you for pointing this out. The sentence was rewritten as suggested by the Reviewer.

6. Line 106. **Current:** “bovine fascioliasis”/ **Suggestion:** “bovine fasciolosis.”

**RESPONSE:** we appreciate this comment and apologize for the mistake. The sentence was rewritten according to the suggested correction.

7. Line 125. **Current:** “...500 samples”/ **Comment:** “How did the authors come up with this samples size? Any sample size formula?”

**RESPONSE:** thank you for mentioning this. Serum and fecal samples obtained from farms (n=500), as well as serum samples obtained from abattoir (n=139) represent convenience samples, and therefore, were not obtained from probabilistic sampling plans, as they included the voluntary participation of regional agricultural establishments in the State of Santa Catarina, located in the south of Brazil.

8. Line 127. **Current:** “...collected from cattle ranging in age from six months to 20 years”/**Suggestion:** “...collected from cattle ranging from six months to 20 years old.”

**RESPONSE:** thank you for pointing this out. The sentence was rewritten as suggested by the Reviewer.

9. Lines 131–142. **Current:** “We found 405 negative and 95 positive results for eggs in the fecal samples. Of 132 the 95 positive animals, 38 (7.6%) were positive for *F. hepatica*, 28 for *F. hepatica* eggs only, and 10 for *F. hepatica* and other parasites: seven also contained eggs of strongylid genera, two *Eimeria* eggs, and one *Strongylidae* and *Eimeria* eggs. The examination also showed that 44 (8.8%) cattle were positive for strongylid genera only and 13 (2.6%) for both strongylid genera and *Eimeria*. Animals positive for other parasites than *F. hepatica* were excluded from the diagnostic performance evaluation of native and recombinant antigens. A total of 139 serum samples were collected from a cattle abattoir located in southern Santa Catarina. The presence of cattle fasciolosis was determined through liver inspection. According to this approach, 10 (7.2%) cattle were diagnosed with *F. hepatica*, with no other parasites investigated during the veterinary inspection”/ **Comment:** “Move to results section. Because this section is for methodology only and not results.”

**RESPONSE:** we appreciate this comment. Now this paragraph has been moved to the results section as suggested by the Reviewer. Furthermore, we have made some improvements to the wording of this paragraph (lines 292-299) to clarify the two independent samples we analyzed (from the farms and the abattoir).

10. Line 131. **Current:** “38 were positive for *F. hepatica*”/ **Comment:** “Were the 38 included in the 139?”

**RESPONSE:** we appreciate this comment and apologize for the lack of clarity in the wording of the study design, which includes two cattle samples obtained independently,

one from farms and the other from abattoir. We rewrote the method section (lines 123-143), separating the description of the samples obtained in each context into subsections to make this information clearer. In this sense, the 38 positive samples for fasciolosis correspond to samples from farms (in which, in total, 500 animals were evaluated), where the disease was investigated through coprological examination (lines 136-143 in the methods section and lines 292-299 in the results section). Among the samples from the abattoir (which totaled 139 animals), 10 were positive for fasciolosis according to liver inspection (lines 127-132 in the methods section and lines 268-272 in the results section).

11. Line 143. **Current:** "Serum samples collected from both the abattoir and farms were processed, divided into aliquots, and stored at -30°C for subsequent ELISA testing"/  
**Comment:** "This suggest that you had 500 serum samples why conduct ELISA on 139 only?"

**RESPONSE:** thank you for mentioning this. As described in the previous item, we apologize for the lack of clarity in the description of the samples used in this research. We reiterate that improvements were made in the writing of the methods section to overcome this issue (lines 123-143). ELISA tests were conducted on both groups: on the 500 samples obtained on the farms and on the 139 obtained at abattoir. In the results section, Tables 1 and 2, and Figure 1, show the analyzes of the ELISA data for cattle at abattoir, and Tables 3 and 4, and Figure 2 correspond to the analyzes of the ELISA data for cattle on farms. These results covered 433 animals, since those that presented positive results in the coprological examination for parasites other than *F. hepatica* were excluded (n=67). Nonetheless, supplementary material shows the analyzes of all farms data (i.e., including those animals that tested positive for other parasites in the coprological examination, totaling 500 cattle) aiming to evaluate the impact of cross-infection on the diagnostic performance of serodiagnosis tests.

12. Table 2. **Current:** "...0.80 (0.46; 0.95), 0.70 (0.38; 0.90), 0.70 (0.38; 0.90)"/  
**Suggestion:** "Recalculate all the ranges of CI, For example 0.80 (0.72-0.85); 0.7 (0.62-0.77). Also include the positive figures unlike only percentage positivity 80% of 139 is 111/139 (80%). They look to be too wide and appears to be out of range, considering (n=139) bovine fascioliasis."

**RESPONSE:** we appreciate this comment and apologize for the lack of clarity in the description of the estimated diagnostic measures, presented on Table 2 for cattle from abattoir and on Table 4 and on Supplementary Table 2 for those from farms. We added on these Tables the numerator and denominator correspondent to the estimate of each diagnostic measure. For example, in Table 2, the estimated sensitivity of 0.80 for *FhES* is derived from the ratio of 8 true positive cases identified by the chosen cutoff point for *FhES* optical density, divided by the 10 positive cases identified by the gold standard method (liver inspection). Also, we checked all the estimated diagnostic measures we presented on Tables 2 and 4 and Supplementary Table 2, as well as their confidence interval estimation. As mentioned on item 3, the wider confidence interval for sensitivity measure is expected due to the rare disease occurrence on the studied samples. Also,



we include a link to an open access repository on the current version of the manuscript where the script used in the data analysis was made available.

13. Table 4. **Current:** "...0.79(0.60;0.90)" / **Suggestion:** "Recalculate all the ranges of CI, e.g (0.79 (0.75–0.82))."

**RESPONSE:** thank you for mentioning this. We apologize for the lack of clarity in the description of the estimated diagnostic measures, presented on Table 4 for cattle from farms. We correct the CI presentation as suggested by the Reviewer and added information regarding numerator and denominator of the estimated diagnostic measures. Please, see the answer presented in the previous item (item 12).

14. General comment. **Current:** "The number of samples differ. You have 500 in initial stage but you are reporting 433"/ **Comment:** "The samples collected should all be analyzed. Where are other 67 samples?"

**RESPONSE:** thank you for mentioning this. We apologize for the lack of clarity in the description of the samples used in this research. We reiterate that improvements were made in the writing of the methods section to overcome this issue (lines 123-143). Please, see the answer presented in the items 9, 10 and 11.

15. General comment. **Current:** "Only 139 serum and 500 feacal samples"/ **Comment:** "For serum samples you analysed only 139 why not analysed serum from all 500 animals so that you compare the results for feacal examination and serology results?"

**RESPONSE:** thank you for mentioning this. We apologize for the lack of clarity in the description of the samples used in this research. We reiterate that improvements were made in the writing of the methods section to overcome this issue (lines 123-143). Please, see the answer presented in the items 9, 10 and 11.

Generally, the research is okay but needs major revision.

1.The number samples are confusing there 500 then 433 and 139. The number of samples should the same or tallying.

**RESPONSE:** thank you for mentioning this. We apologize for the lack of clarity in the description of the samples used in this research. In the method section, the subsection entitled "Characteristics of the cattle included in the study" has been revised and restructured (lines 123-143) aiming to separately describe the two studied cattle groups, the one from farms and the other from abattoir.

2. The Number of positive should indicated and in brackets you put the positive percentage eg 111/139 (80%) unlike only 80% or 0.80. This can be misleading to some readers.

**RESPONSE:** thank you for mentioning this. We revised Tables 2 and 4 and Supplementary Table 2 aiming to add the numerator and denominator of the estimated diagnostic measures. Please, see the answer presented in the item 12.

3. The Confidence interval should be recalculated it is misleading or misreading. This is a range 95% CI 80% (72-85%) OR 95% CI 0.80 (0.72-0.85) OR 95% CI 0.80 (0.72; 0.85)

**RESPONSE:** thank you for mentioning this. We correct the CI presentation as suggested by the Reviewer. Also, we checked all the estimated diagnostic measures we presented on Tables 2, 4 and Supplementary Table 2, as well as their confidence interval estimation. Please, see the answer presented in the item 12.

We thank the reviewer for their helpful suggestions that improved the message of our manuscript. Please find in below our point-to-point answers and commentaries on some text improvements we have made. In the revised version of our manuscript, major changes/insertions are outlined in red.

Independent Review Report, Reviewer 1

1. Line 21. **Current:** “cattle fasciolosis”/ **Suggestion:** “chronic fasciolosis”.

**RESPONSE:** thank you for mention this. We replaced the term as suggested by the Reviewer.

2. *Fasciola gigantica* is more prevalent in Kettle, which species of *Fasciola* is used in this article? How is the *Fasciola* species confirmed?

**RESPONSE:** thank you for pointing this out. *Fasciola hepatica* is most prevalent in America. In our study, we employed both native and recombinant *F. hepatica* antigens.

For the native antigens, *F. hepatica* specimens was collected from a local cattle abattoir. The classification of these parasites as *F. hepatica* was based on morphological characteristics and parasite size during the veterinary inspection (lines 127-132).

In contrast, for the recombinant antigen, a genetic sequence encoding the cathepsin of *F. hepatica* retrieved from a genetic sequence bank was utilized (lines 181-187).

3. Lines 131–144. How did you differentiate the *Fasciola* species in Cattle? *Fasciola gigantica* is more common in cattle. How did you make a definitive diagnosis of *Fasciola hepatica*?

**RESPONSE:** thank you for bringing this to our attention. *F. hepatica* occurs more frequently in America. For the native antigens, the identification of *F. hepatica* was based on the morphological characteristics of the parasite. For the recombinant antigen, a genetic sequence coding for the *F. hepatica* antigen was used. The genetic sequence is described in the materials and methods of the manuscript (lines 181–187).

4. Line 223. In which temperature and condition? For TMB the time is 15-20 min. For your research, the color will be dim and therefore light absorption will be low.

**RESPONSE:** thank you for pointing this out. This sentence was rewritten (lines 220–223). After incubation at room temperature in the dark for 10- 20 min, the reaction was stopped with 50 $\mu$ L of 0.1 M sulfuric acid.

The sentence has been revised to reflect adjustments made in accordance with the ELISA protocol utilized. In light of TMB's photosensitivity, rigorous measures were instituted to ensure the accurate execution of the ELISA protocol. Detailed procedures have been outlined in the methods section of the manuscript.

Regarding the absorbance values highlighted by the reviewer, our hypothesis posits a plausible correlation between antigen composition and the observed variations in absorbance values. The heterogeneous protein composition of native antigens suggests a propensity for higher absorbance values. Conversely, the singular nature of the recombinant antigen may contribute to comparatively lower absorbance values.

5. Line 263. The purification of *FhSA*, *FhES*, and *FhrCL-1* proteins was shown on SDS-PAGE.

**RESPONSE:** thank you for bringing this to our attention. We conducted an analysis of the purification of both native and recombinant antigens using SDS-PAGE; data are not shown. We followed the purification methodology described in the methods section, lines 172-177 and 196-199 for the native and recombinant antigens, respectively.

6. Line 281. ... positive results were false.

**RESPONSE:** thank you for pointing this out. This sentence was rewritten (lines 282 - 285). Since the fasciolosis prevalence is low (10 positive cases in 139 cattle), we observed a large number of false positives and consequently a low PPV: only 8 of the 33 positive results were true positive, suggesting the serological tests cannot be used to confirm the presence of the disease.

7. Line 308. Overall, these results....

**RESPONSE:** thank you for pointing this out. This sentence was rewritten. Overall, these results show that samples positive for fasciolosis presented higher absorbance values (lines 329 - 330).

What sera were used for check the cross reaction? The sera of patients with hydatidosis, taeniasis, toxocariasis, etc. have a cross-reaction with fascioliasis. Especially in sheep and cattle.

**RESPONSE:** we appreciate this comment. During the cattle screening process on farms, coprological examination was used to screen the fecal samples for the presence of parasites eggs. The results of the coprological examination revealed the presence of *F. hepatica* eggs and other parasites, with some samples demonstrating concomitant infections. For the analysis presented in the result section, conducted in order to determine the cutoff points and diagnostic performance measures (sensitivity, specificity, positive and negative predictive values) of the serological tests (Tables 3 and 4 and Figure 2), samples positive for other parasites than *F. hepatica* were excluded (n=67).

Subsequently, these samples were used to explore their absorbance values in relation to the cutoff points established for the serological tests. Furthermore, sensitivity analysis was carried out by adjusting models that considered all samples (those only diagnosed with other parasites were classified in the negative group and those also diagnosed with *F. hepatica* in the positive group), with the aim of evaluating possible changes in the tests performance measures (Supplementary Tables 1 and 2 and Supplementary Figure 1). The description of the positive samples (for fasciolosis and/or other parasites) is now described in detail in lines 292-299.

The reviewer raised a pertinent issue concerning the assessment of cross-infection with other parasites. The utilization of serum samples from animals harboring other parasites is deemed ideal for evaluating cross-infection. Our group is just starting research into diagnostic tools for cattle fasciolosis, and we don't have serum samples from cattle that are positive for other parasites. In addition, COVID-19 has impacted the development of our research. The expectation within our laboratory is to obtain bovine

serum samples demonstrating positivity for other parasites and incorporate them into the sample panel for the development of a lateral flow assays.

8. Table 1. Add OD.

**RESPONSE:** thank you for mention this. We added the OD term in Table 1 as suggested by the Reviewer.

9. Table 2. Add OD.

**RESPONSE:** thank you for mention this. We added the OD term in Table 2, in the line correspondent to the cutoff value of each evaluated serodiagnosis test. The other information are diagnostic performance measures.

10. Table 3. Add OD.

**RESPONSE:** thank you for mention this. We added the OD term in Table 1 as suggested by the Reviewer.

11. Table 4. Add OD.

**RESPONSE:** thank you for mention this. We added the OD term in Table 4, in the line correspondent to the cutoff value of each evaluated serodiagnosis test. The other information are diagnostic performance measures.

General comment.

The following paragraph should be rewritten. The results show whether it is in the stool or in the serum. Please rewritten clearly. It is difficult to distinguish the eggs of *Fasciola* species by microscopic observation. How was the diagnosis made?

“We found 405 negative and 95 positive results for eggs in the fecal samples. Of 132 the 95 positive animals, 38 (7.6%) were positive for *F. hepatica*, 28 for *F. hepatica* eggs only, and 10 for *F. hepatica* and other parasites: seven also contained eggs of strongylid genera, two *Eimeria* eggs, and one *Strongylidae* and *Eimeria* eggs. The examination also showed that 44 (8.8%) cattle were positive for strongylid genera only and 13 (2.6%) for both strongylid genera and *Eimeria*. Animals positive for other parasites than *F. hepatica* were excluded from the diagnostic performance evaluation of native and recombinant antigens. A total of 139 serum samples were collected from a cattle abattoir located in southern Santa Catarina. The presence of cattle fasciolosis was determined through liver inspection. According to this approach, 10 (7.2%) cattle were diagnosed with *F. hepatica*, with no other parasites investigated during the veterinary inspection.”

**RESPONSE:** we appreciate this comment and apologize for the for the lack of clarity in the description of the samples used in this research. We rewritten this paragraph, as following: “The coprological examination resulted in 405/500 (81%) negative and 95/500 (19%) positive results. Of the 95 positive results, 28/500 (5.6%) were positive only for *F. hepatica* eggs, and 10/500 (2%) for *F. hepatica* and other parasites: 7/500 (1.4%) also contained *Strongylidae* eggs, 2/500 (0.4%) *Eimeria* eggs, and 1/500 (0.2%) *Strongylidae* and *Eimeria* eggs. The examination also showed that 44/500 (8.8%) cattle were positive only for *Strongylidae* eggs and 13/500 (2.6%) for both *Strongylidae* and

*Eimeria* eggs. Animals positive for other parasites than *F. hepatica* (n = 67) were excluded from the diagnostic performance evaluation of native and recombinant antigens described below” (lines 292-299 in the results section).

The detection of *F. hepatica* eggs in fecal samples was conducted by proficient laboratory technicians employing the sedimentation protocol. Each sample underwent diagnostic assessment in triplicate, as outlined in lines 136-143 of the methods section.

The section of the manuscript titled "Characteristics of the cattle included in the study" has been revised and restructured. Subtitles have been added to elucidate the number of samples and cattle groups we studied as well as the methodology employed to conduct the comparison with gold standard methods for the diagnostic performance estimation of the ELISA tests.

Re: Spectrum00095-24R1 (Diagnosis of fasciolosis antibodies in Brazilian cattle through enzyme-linked immunosorbent assay (ELISA) employing both native and recombinant antigens)

Dear Dr. GUILHERME DRESCHER:

Your manuscript has been accepted, and I am forwarding it to the ASM production staff for publication. Your paper will first be checked to make sure all elements meet the technical requirements. ASM staff will contact you if anything needs to be revised before copyediting and production can begin. Otherwise, you will be notified when your proofs are ready to be viewed.

**Data Availability:** ASM policy requires that data be available to the public upon online posting of the article, so please verify all links to sequence records, if present, and make sure that each number retrieves the full record of the data. If a new accession number is not linked or a link is broken, provide production staff with the correct URL for the record. If the accession numbers for new data are not publicly accessible before the expected online posting of the article, publication may be delayed; please contact ASM production staff immediately with the expected release date.

**Publication Fees:** For information on publication fees and which article types have charges, please visit our [website](#). We have partnered with Copyright Clearance Center (CCC) to collect author charges. If fees apply to your paper, you will receive a message from no-reply@copyright.com with further instructions. For questions related to paying charges through RightsLink, please contact CCC at ASM\_Support@copyright.com or toll free at +1-877-622-5543. CCC makes every attempt to respond to all emails within 24 hours.

**ASM Membership:** Corresponding authors may [join or renew ASM membership](#) to obtain discounts on publication fees. Need to upgrade your membership level? Please contact Customer Service at [Service@asmusa.org](mailto:Service@asmusa.org).

**PubMed Central:** ASM deposits all Spectrum articles in PubMed Central and international PubMed Central-like repositories immediately after publication. Thus, your article is automatically in compliance with the NIH access mandate. If your work was supported by a funding agency that has public access requirements like those of the NIH (e.g., the Wellcome Trust), you may post your article in a similar public access site, but we ask that you specify that the release date be no earlier than the date of publication on the Spectrum website.

**Embargo Policy:** A press release may be issued as soon as the manuscript is posted on the [Spectrum Latest Articles webpage](#). The corresponding author will receive an email with the subject line "ASM Journals Author Services Notification" when the article is available online.

The ASM Journals program strives for constant improvement in our submission and publication process. Please tell us how we can improve your experience by taking this quick [Author Survey](#).

Thank you for submitting your paper to Spectrum.

Sincerely,  
Artem Rogovskyy  
Editor  
Microbiology Spectrum